Where does Dianthus Therapeutics's cash flow data come from?

Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q3 '25	Q2 '25	Q1 '25	Q4 '24
Net income	-$40.83M-38.4%	-$36.77M-46.0%	-$31.63M-79.6%	-$29.51M-115%	-$28.44M-169%
Depreciation and amortization	$32K+18.5%	$27K+8.0%	$30K+30.4%	$27K+22.7%	$26K+30.0%
Stock-based compensation	$10.6M+99.5%	$5.79M+50.9%	$5.71M+84.0%	$5.32M+161%	$3.92M+440%
Change in accounts receivable	$1.18M+17.8%	$4.96M—	——	$1M—	——
Change in other assets	$2.33M+21.9%	$35K-90.7%	——	$1.91M+894%	$1.17M—
Change in deferred revenue	$849K+1,589%	$4.76M—	-$66K—	-$57K—	$2.39M+5,089%
Non-cash operating lease expense	$44K-58.5%	$72K-20.9%	$69K-21.6%	$106K+24.7%	$52K-37.3%
Net cash from operating activities	-$28.86M-4.4%	-$30.56M-43.7%	-$23.89M-64.5%	-$27.63M-84.9%	-$27.44M-132%
Capital expenditures	$10K-58.3%	$5K-80.0%	$46K+171%	$24K-25.0%	$31K+210%
Purchases of investments	$238.59M+254%	$279.84M+0.5%	$33.11M+386%	$67.32M+229%	$108.08M+312%
Proceeds from maturities/sales of investments	$104.63M+27.4%	$78.57M+314%	$59.6M+645%	$82.14M+448%	$85M+372%
Net cash from investing activities	-$133.97M-1,006%	-$201.28M+22.4%	$26.45M—	$14.79M+369%	-$23.11M—
Proceeds from issuance of common stock	$120K-7.0%	$187K—	——	$129K—	$39.2M+784,100%
Net cash from financing activities	$739.41M+459,161%	$274.51M+92,641%	$568K—	$161K-99.9%	$39.68M—
Net increase (decrease) in cash	$576.58M+4,649%	$42.68M+115%	——	-$12.68M-106%	-$10.88M—
Accounts Payable Accrued Expenses And Operating Lease Liabilities	$7M+567%	$3M-46.8%	$3.09M-4.8%	-$1.5M+49.8%	$2.28M+42.2%
Accretion (Amortization) of Discounts and Premiums, Investments	$1.22M-35.9%	$2.31M-1.3%	$1.1M+160%	$1.9M+267%	$2.74M+419%
Depreciation	$32K+18.5%	$27K+8.0%	$30K+30.4%	$27K+22.7%	$26K+30.0%
Gain Loss On Investment In Former Related Parties	-$302K-6,140%	——	——	$5K—	——
Deferred revenue	$849K+1,589%	$4.76M—	-$66K—	-$57K—	$2.39M+5,089%
Increase (Decrease) in Other Operating Assets	$2.12M+206%	-$89K-105%	——	-$2M-483%	$5.05M+387%
Increase (Decrease) in Prepaid Expense and Other Assets	$2.33M+21.9%	$35K-90.7%	——	$1.91M+894%	$1.17M—
Increase Decrease In Receivable From Former Related Party	$0+100%	——	——	-$807K—	——
Operating lease right-of-use asset amortization	$44K-58.5%	$72K-20.9%	$69K-21.6%	$106K+24.7%	$52K-37.3%
Payments for Capital Improvements	$10K-58.3%	$5K-80.0%	$46K+171%	$24K-25.0%	$31K+210%
Proceeds From Sale And Maturity Of Available For Sale Securities	$104.63M+27.4%	$78.57M+314%	$59.6M+645%	$82.14M+448%	$85M+372%
Payments Of Issuance Costs Public Offering	$1.34M—	——	——	$0—	——
Proceeds From Issuance Of Common Stock Public Offering	$677.62M—	——	——	$0—	——
Proceeds From Warrant Exercises	$1K0.0%	——	——	$1K—	——
Issuance Costs In Connection With Public Offering Included In Accounts Payable	$50K—	——	——	$0—	——
Issuance Costs In Connection With Public Offering Included In Accrued Expenses	$151K—	——	——	$0—	——
Receivable Associated With Exercise Of Stock Options	$6.45M—	——	——	$0—	——
Free cash flow	-$28.87M-4.4%	-$30.56M-43.5%	-$23.94M-64.6%	-$27.65M-84.7%	-$27.48M-132%
Free cash flow	-$28.87M-4.4%	-$30.56M-43.5%	-$23.94M-64.6%	-$27.65M-84.7%	-$27.48M-132%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Dianthus Therapeutics's cash flow data come from?: Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.